Tin tức & Cập nhật
Lọc theo Chuyên ngành:
H. pylori eradication eases metabolic dysfunction, steatosis in NAFLD
Among patients with nonalcoholic fatty liver disease (NAFLD), eradication treatment against Helicobacter pylori may help improve liver steatosis and metabolic parameters, a recent study has found.
H. pylori eradication eases metabolic dysfunction, steatosis in NAFLD
20 Nov 2022Noninvasive scores use LSM to detect cirrhosis, advance fibrosis in NAFLD
Using liver stiffness measurements (LSM) combined with routine clinical parameters, Agile 3+, and Agile 4, both noninvasive scoring methods, can accurately identify advanced fibrosis (AF) and cirrhosis, respectively, in patients with nonalcoholic fatty liver disease (NAFLD), reports a new study.
Noninvasive scores use LSM to detect cirrhosis, advance fibrosis in NAFLD
16 Nov 2022Bariatric surgery provides cardioprotection in patients with severe obesity, NAFLD
Patients with severe obesity and nonalcoholic fatty liver disease (NAFLD) appear to benefit from bariatric surgery, which significantly reduces the risk of cardiovascular disease (CVD), a study has found.
Bariatric surgery provides cardioprotection in patients with severe obesity, NAFLD
09 Nov 2022Alcohol-related liver disease poses increased risk of cardiovascular disease
Patients with biopsy-proven alcohol-related liver disease (ALD) appear to have a higher frequency of cardiovascular disease (CVD) than their counterparts without ALD, according to a study. The increased rates are especially pronounced just after ALD diagnosis.
Alcohol-related liver disease poses increased risk of cardiovascular disease
07 Nov 2022Third-dose vaccine beats tolerance in cirrhotic COVID-19 patients
A third-dose administration of a COVID-19 mRNA vaccine results in a more substantial decrease in COVID-19 in patients with cirrhosis compared with the general population, according to a study. This suggests that the third dose can overcome vaccine hyporesponsiveness in this population.
Third-dose vaccine beats tolerance in cirrhotic COVID-19 patients
06 Nov 2022Slow disease progression seen in people with NAFLD
A 23-year longitudinal follow-up in a population-based cohort has shown a slowly progressive trend in nonalcoholic fatty liver disease (NAFLD), with liver-related outcomes affecting only a small number of people, reports a recent study.
Slow disease progression seen in people with NAFLD
05 Nov 2022Vebicorvir plus entecavir safe, effective in chronic HBV patients
The addition of vebicorvir to entecavir in treatment-naïve patients with chronic hepatitis B virus (HBV) infection provides further antiviral activity, with a positive safety and tolerability profile, results of a phase II trial have shown.
Vebicorvir plus entecavir safe, effective in chronic HBV patients
03 Nov 2022Freshwater fish-based diet eases liver steatosis in NAFLD patients
Adherence to a freshwater fish-based diet helps regulate the gut microbiota and its metabolites, suggesting benefits in individuals with nonalcoholic fatty liver disease (NAFLD), reveals a study.